Novel MicroRNA Reporter Uncovers Repression of Let-7 by GSK-3β

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Guo, Rong ^a   Abdelmohsen, Kotb ^a   Morin, Patrice J ^a,b   Gorospe, Myriam ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b American Association for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LUCIFERASE; MICRORNA; PROTEIN KINASE INHIBITOR; PROTEIN P53; MIRNLET7 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BIOSYNTHESIS; CANCER CELL CULTURE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; OVARY CANCER; PROTEIN FUNCTION; REPORTER GENE; CELL AGING; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL AGING; CELL LINE, TUMOR; FEMALE; GENES, TUMOR SUPPRESSOR; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879478452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066330     Document Type: Article

References (62)

1. Nana-Sinkam SP, Croce CM, (2013) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 93: 98-104.
2. Fabian MR, Sonenberg N, Filipowicz W, (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-79.
3. Djuranovic S, Nahvi A, Green R, (2012) miRNA-Mediated Gene Silencing by Translational Repression Followed by mRNA Deadenylation and Decay. Science 13: 237-240.
4. Melo SA, Esteller M, (2010) Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585: 2087-2099.
5. Grammatikakis I, Gorospe M, Abdelmohsen K, (2013) Modulation of Cancer Traits by Tumor Suppressor microRNAs. Int J Mol Sci. 2013 Jan 16 14(1): 1822-1842.
6. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, et al. (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 3: e2436.
7. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, et al. (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906.
8. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, et al. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89.
9. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T, (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853-858.
10. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004.
11. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research 64: 3753-3756.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
13. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, et al. (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590-7595.
14. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, et al. (2012) MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth. PLoS ONE 7: e32832.
15. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, et al. (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764.
16. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, et al. (2010) Regression of murine lung tumors by the let-7 microRNA. Oncogene 29: 1580-1587.
17. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME, (2010) The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 17: F19-36.
18. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
19. Lee YS, Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21, 1025-1030.
20. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, et al. (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400-11405.
21. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ, (2007) High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6: 5.
22. Wang T, Zhang X, Obijuru L, Laser J, Aris V, et al. (2007) A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46: 336-347.
23. Mayr C, Hemann MT, Bartel DP, (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579.
24. Esquela-Kerscher A Trang P, Wiggins JF, Patrawala L, Cheng A, et al. (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764.
25. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, et al. (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903-3908.
26. Winter J, Diederichs S, (2011) MicroRNA biogenesis and cancer. Methods Mol Biol 676: 3-22.
27. Ketting RF, (2011) microRNA Biogenesis and Function: An overview. Adv Exp Med Biol 700: 1-14.
28. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, et al. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
29. Wang Z, Lin S, Li JJ, Xu Z, Yao H, et al. (2011) MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1∼let-7d via noncanonical E-box. J Biol Chem 286: 39703-39714.
30. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, et al. (2011) Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS ONE. 6: e24429.
31. Wang DJ, Legesse-Miller A, Johnson EL, Coller HA, (2012) Regulation of the let-7a-3 Promoter by NF-κB. PLoS ONE 7: e31240.
32. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. (2006) Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20: 2202-2207.
33. Wulczyn FG, Smirnova L, Rybak A, Brandt C, Kwidzinski E, et al. (2007) Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J 21: 415-426.
34. Heo I, Joo C, Cho J, Ha M, Han J, et al. (2008) Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 32: 276-284.
35. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, et al. (2011) Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147: 1066-1079.
36. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, et al. (2009) Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 106: 3384-3389.
37. Baldwin WS, Curtis SW, Cauthen CA, Risinger JI, Korach KS, et al. (1998) BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell Dev Biol Anim 34: 649-654.
38. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, et al. (2004) Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 47: 999-1007.
39. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, et al. (1989) Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63: 280-288.
40. Chen X, Zhang H, Aravindakshan JP, Gotlieb WH, Sairam MR, (2011) Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization. Oncogene 30: 2874-2887.
41. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ, (2004) The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3′UTR. Genes Dev 18: 132-137.
42. Marasa BS, Srikantan S, Masuda K, Abdelmohsen K, Kuwano Y, et al. (2009) Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal ra69: 1126.
43. Abdelmohsen K, Srikantan S, Tominaga K, Kang MJ, Yaniv Y, et al. (2012) Growth inhibition by miR-519 via multiple p21-inducing pathways. Mol Cell Biol 32: 2530-2548.
44. Leost M, Schultz C, Link A, Wu YZ, Biernat J, et al. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 267: 5983-5994.
45. Ghosh JC, Altieri DC, (2005) Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 11: 4580-4588.
46. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-501.
47. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593.
48. Furlong MT, Morin PJ, (2000) Rare activation of the TCF/beta-catenin pathway in ovarian cancer. Gynecol Oncol 77: 97-104.
49. Boominathan L, (2010) The TA-p73 functions as a lung tumor suppressor by increasing the expression of miRNA, let-7. Nature Precedings 2010: 4252
50. Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, et al. (2012) GSK-3β: A Bifunctional Role in Cell Death Pathways. International Journal of Cell Biology 35: 1052-1059.
51. Stavridi ES, Halazonetis TD, (2004) p53 and stress in the ER. Genes Dev. 18: 241-244.
52. Seo YH, Jung HJ, Shin HT, Kim YM, Yim H, et al. (2008) Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation. Aging Cell 7: 894-907.
53. Kulikov R, Boehme KA, Blattner C, (2005) Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 25: 7170-7180.
54. Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, et al. (2013) Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS ONE 8: e55289.
55. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, et al. (2011) Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs 22: 978-985.
56. Luo J, (2009) Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194-200.
57. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, et al. (2009) An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3β. Anticancer Agents Med Chem 9: 1114-1122.
58. Cao Q, Lu X, Feng YJ, (2006) Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16: 671-677.
59. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD, (2005) Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65: 2076-2081.
60. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, et al. (2005) Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005 334: 1365-1373.
61. Ma C, Wang J, Gao Y, Gao TW, Chen G, et al. (2007) The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 67: 7756-7764.
62. Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, et al. (2005) Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 65: 5792-5801.